Skip to main content

REVIEW article

Front. Cell. Infect. Microbiol.
Sec. Intestinal Microbiome
Volume 14 - 2024 | doi: 10.3389/fcimb.2024.1446580
This article is part of the Research Topic Interaction of Microbiota and Metabolomic Disorders View all 5 articles

Broadening horizons: Intestinal microbiota as a novel biomarker and potential treatment for hypertensive disorders during of pregnancy

Provisionally accepted
Min Wang Min Wang 1Lianwen Zheng Lianwen Zheng 1Shuai Ma Shuai Ma 1Dong hai Zhao Dong hai Zhao 2XU YING XU YING 1*
  • 1 Department of Obstetrics and Gynecology, Second Hospital of Jilin University, Changchun, China
  • 2 Department of Physiology, School of Basic Medicine, Jilin Medical University, Jilin, Jilin, China

The final, formatted version of the article will be published soon.

    Hypertensive disorders of pregnancy (HDP) are severe complications of pregnancy with high morbidity and are a major cause of increased maternal and infant morbidity and mortality. Currently, there is a lack of effective early diagnostic indicators and safe and effective preventive strategies for HDP in clinical practice, except for monitoring maternal blood pressure levels, the degree of proteinuria, organ involvement and fetal conditions. The intestinal microbiota consists of the gut flora and intestinal environment, which is the largest microecosystem of the human body and participates in material and energy metabolism, gene expression regulation, immunity regulation, and other functions. During pregnancy, due to changes in hormone levels and altered immune function, the intestinal microecological balance is affected, triggering HDP. A dysregulated intestinal microenvironment influences the composition and distribution of the gut flora and changes the intestinal barrier, driving beneficial or harmful bacterial metabolites and inflammatory responses to participate in the development of HDP and promote its malignant development. When the gut flora is dysbiotic and affects blood pressure, supplementation with probiotics and dietary fibre can be used to intervene. In this review, the interaction between the intestinal microbiota and HDP was investigated to explore the feasibility of the gut flora as a novel biomarker of HDP and to provide a new strategy and basis for the prevention and treatment of clinical HDP.

    Keywords: intestinal microbiota, gut flora, Hypertensive disorders of pregnancy, Metabolism Disorder, Treatment, Expression, biomarkers

    Received: 10 Jun 2024; Accepted: 24 Jul 2024.

    Copyright: © 2024 Wang, Zheng, Ma, Zhao and YING. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: XU YING, Department of Obstetrics and Gynecology, Second Hospital of Jilin University, Changchun, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.